"Checkpoint Kinase 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A serine/threonine-specific protein kinase which is encoded by the CHEK1 gene in humans. Checkpoint kinase 1 (also known as Chk1) coordinates DNA damage response and cell cycle checkpoint response. Under these conditions, activation of Chk1 results in the initiation of cell cycle checkpoints, cell cycle arrest, DNA repair and cell death, to prevent damaged cells from progressing through the cell cycle.
| Descriptor ID |
D000071877
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.143
|
| Concept/Terms |
Checkpoint Kinase 1- Checkpoint Kinase 1
- Chk1 Kinase
- Chk1 Protein Kinase
- Protein Kinase, Chk1
- Checkpoint-1 Kinase
|
Below are MeSH descriptors whose meaning is more general than "Checkpoint Kinase 1".
Below are MeSH descriptors whose meaning is more specific than "Checkpoint Kinase 1".
This graph shows the total number of publications written about "Checkpoint Kinase 1" by people in this website by year, and whether "Checkpoint Kinase 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 3 | 3 |
| 2003 | 0 | 5 | 5 |
| 2004 | 0 | 7 | 7 |
| 2005 | 0 | 6 | 6 |
| 2006 | 0 | 7 | 7 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 7 | 7 |
| 2010 | 0 | 7 | 7 |
| 2011 | 0 | 7 | 7 |
| 2012 | 0 | 5 | 5 |
| 2013 | 0 | 3 | 3 |
| 2014 | 0 | 6 | 6 |
| 2016 | 2 | 1 | 3 |
| 2017 | 4 | 1 | 5 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 3 | 4 |
| 2022 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Checkpoint Kinase 1" by people in Profiles.
-
Tumour-intrinsic PDL1 signals regulate the Chk2 DNA damage response in cancer cells and mediate resistance to Chk1 inhibitors. Mol Cancer. 2024 Oct 30; 23(1):242.
-
Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade. Nat Commun. 2023 03 22; 14(1):1566.
-
ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization. Cell Rep. 2022 01 11; 38(2):110216.
-
Genetic insights into biological mechanisms governing human ovarian ageing. Nature. 2021 08; 596(7872):393-397.
-
A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515). Pediatr Blood Cancer. 2021 09; 68(9):e29065.
-
Overexpression of TopBP1, a canonical ATR/Chk1 activator, paradoxically hinders ATR/Chk1 activation in cancer. J Biol Chem. 2021 Jan-Jun; 296:100382.
-
Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor. Clin Cancer Res. 2021 04 01; 27(7):1864-1874.
-
A Tiered Female Ovarian Toxicity Screening Identifies Toxic Effects of Checkpoint Kinase 1 Inhibitors on Murine Growing Follicles. Toxicol Sci. 2020 10 01; 177(2):405-419.
-
Ubiquitination of the DNA-damage checkpoint kinase CHK1 by TRAF4 is required for CHK1 activation. J Hematol Oncol. 2020 05 01; 13(1):40.
-
Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints. Int J Radiat Biol. 2021; 97(8):1121-1128.